Plain-English translation of NCT04580134 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Schizophrenia research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing , a medication that has been used for decades but may work especially well for certain people with schizophrenia, schizoaffective disorder, or bipolar disorder with psychotic symptoms. Researchers believe that people with a specific brain activity pattern (called 'Biotype 1') may respond much better to this medication than others do. The study will compare how well the medication works compared to a more standard antipsychotic treatment.
Currently, many people with these serious mental illnesses don't get enough relief from standard antipsychotic medications. This trial exists to find out whether the treatment works dramatically better in a specific group of patients, which could help doctors choose the right medication for the right person from the start.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to take either the test medication () or a standard comparison medication () as an outpatient. You would take the medication by mouth daily, with doses gradually increased to a target level, and attend regular study visits for blood tests, symptom checks, and EEG (a test measuring brain electrical activity). The study would also provide additional medications to help manage side effects like sleep problems or shaking. Throughout the study, researchers would track how much your psychotic symptoms improve.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
United States